Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk
Information source: University of Oslo School of Pharmacy
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Renal Transplant Recipients
Intervention: Zenapax®, CellCept® and prednisolone (Drug); Sandimmun Neoral®, CellCept® and prednisolone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: University of Oslo School of Pharmacy Official(s) and/or principal investigator(s): Anders Hartmann, MD, Principal Investigator, Affiliation: Rikshospitalet, Section of Nephrology
Summary
To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal
allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match,
receiving immunosuppressive therapy with A) Zenapax (5 doses), CellCept (1. 5 g bid.,
aiming for TDM for total trough concentrations of 2-6 mg/L) and prednisolone or B) Sandimmun
Neoral (full dose), CellCept (1. 0 g bid.) and prednisolone.
Clinical Details
Official title: Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax, CellCept and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral, CellCept and Prednisolone) on the Outcome of Renal Function and Acute Rejection in 0 DR Mis-Matched Renal Allograft Recipients
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: The primary efficacy endpoint is the renal function, evaluated by 51Cr-EDTA clearance and normalized for 1.73 m2 body-surface, at 12 months posttransplant.
Secondary outcome: • Combined patient and graft survival at 12 months posttransplant.• Proportion of patients with biopsy-proven acute rejection or acute rejection (biopsy proven + presumptive) episode at 3 and 12 month posttransplant. • Incidence and severity of hypertension at 10 weeks and 12 months posttransplant. • Incidence and severity of dyslipidemia at 10 weeks and 12 months posttransplant. • Incidence of glucose intolerance at 10 weeks and 12 months posttransplant. • Incidence of treatment failure at 12 months posttransplant. • Success rate of TDM guided CellCept® dosing at 3 months posttransplant. • Infection rate.
Detailed description:
Primary Objective To compare renal function (51Cr-EDTA clearance) 12 months posttransplant,
in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR
mis-match, receiving immunosuppressive therapy with A) Zenapax® (5 doses), CellCept® (1. 5 g
bid., aiming for TDM for total trough concentrations of 2-6 mg/L) and prednisolone or B)
Sandimmun Neoral® (full dose), CellCept® (1. 0 g bid.) and prednisolone.
Secondary Objectives To compare the two treatment groups with regard to: patient and graft
survival (12 months), biopsy-proven and presumptive rejection episodes (3 and 12 months),
posttransplant (12 months) incidence and severity of hypertension, hyperlipidemia, glucose
intolerance, incidence of infection and tolerability and “success rate” of TDM guided
CellCept® dosing in a calcineurin inhibitor-free immunosuppressive protocol over 12 months.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 1. Patients of either gender above 18 years of age. 2. Patients who are recipients of
primary, 0 DR mis-matched renal allografts from cadaveric donors (aged between 10 and
70 years).
3. Patients who are single organ recipients (kidney only). 4. If the patients are
women of childbearing potential, they must use safe contraceptives.
5. Patients not previously treated with Zenapax® or Simulect®. 6. Patients must be
capable to understand the information given about the study, including purpose and
risks, and they must sign a statement of informed consent in accordance with the
Helsinki declaration.
7. Patients with white blood count greater than 2. 5 x 109 /L (IU), platelet count
greater than 100 x 109 /L (IU) or haemoglobin greater than 6 g/dL at the time of
entry into the study.
Exclusion Criteria:
- 1. Patients who are recipients of HLA-identical renal transplants. 2. PRA positive
(>20%) patients at any time the alst 6 months. 3. Patients who are unable to stay
outside hospital as outpatients for 3 months.
4. Patients who are unable to receive oral medication. 5. Patients with active peptic
ulcer disease. 6. Patients with active infection. 7. Patients with disorders which
might interfere with their ability to absorb oral medication, such as severe
diarrhoea or patients with previously diagnosed diabetic gastroenteropathy.
8. Patients who are pregnant or nursing mothers. 9. Patients with ongoing
malignancies, excluding adequately treated skin carcinoma.
10. Patients not able to adhere to the investigational immunosuppressive therapy.
11. Patients receiving bile-acid sequestants.
Locations and Contacts
Additional Information
Starting date: January 2002
Last updated: November 30, 2005
|